Objective-Apolipoprotein A-I (apoA-I) mimetic peptides have antiatherogenic properties of high-density lipoprotein in vitro and have been shown to inhibit atherosclerosis in vivo. It is unclear, however, if each in vitro antiatherogenic property of these peptides translates to a corresponding activity in vivo, and if so, which of these contributes most to reduce atherosclerosis. Approach and Results-The effect of 7 apoA-I mimetic peptides, which were developed to selectively reproduce a specific component of the antiatherogenic properties of apoA-I, on the development of atherosclerosis was investigated in apolipoprotein E-deficient mice fed a high-fat diet for 4 or 12 weeks. The peptides include those that selectively upregulate cholesterol efflux, or are anti-inflammatory, or have antioxidation properties. All the peptides studied effectively inhibited the in vivo development of atherosclerosis in this model to the same extent. However, none of the peptides had the same selective effect in vivo as they had exhibited in vitro. None of the tested peptides affected plasma lipoprotein profile; capacity of plasma to support cholesterol efflux was increased modestly and similarly for all peptides. Conclusions-There is a discordance between the selective in vitro and in vivo functional properties of apoA-I mimetic peptides, and the in vivo antiatherosclerotic effect of apoA-I-mimetic peptides is independent of their in vitro functional profile. Comparing the properties of apoA-I mimetic peptides in plasma rather than in the lipid-free state is better for predicting their in vivo effects on atherosclerosis. Visual Overview-An online visual overview is available for this article. Supplement. The peptides included ELK-2A2K2E, potent in cholesterol efflux, ELKA-CH2, a selective inhibitor of CD11b expression in monocytes, ELK-2A, a selective inhibitor of VCAM-1 (vascular cell adhesion molecule 1) expression in endothelial cells, and 5A-CH1, which inhibits low-density lipoprotein (LDL) oxidation. In addition, we examined the synergistic effect of ELK-2A2K2E and 5A-C1 (each peptide was added at half the concentration compared with that when tested individually). This peptide combination was selected on the basis of reproducing, at least in vitro, all 4 of the antiatherogenic profiles under study ( Figure I in the online-only Data Supplement). Finally, the well-characterized and versatile peptide 5A was also studied under the same conditions.
A polipoprotein A-I (apoA-I) is the key structural element of high-density lipoprotein (HDL). While the best studied and probably the most important function of HDL is its role as a specific cholesterol acceptor in the reverse cholesterol transport pathway, HDL has many other functions, including anti-inflammation, antioxidation, antiproliferation, and antithrombosis. 1 ApoA-I mimetic peptides were designed to recreate the various beneficial functions of HDL, mostly in the context of protection against atherosclerosis. Most apoA-I mimetics have no homology to the primary structure of apoA-I, instead mimicking a key element of its secondary structure, namely a 22-mer amphipathic α-helix, which is believed to be responsible for lipid-acceptor properties of apoA-I. ApoA-I mimetics have been reported to be effective acceptors of cellular cholesterol and are capable of selectively reproducing functional aspects of HDL in vitro. They have also been shown to be atheroprotective in vivo in animal models (for review see Sviridov and Remaley 2 ). ApoA-I mimetic peptides, thus, offer the opportunity to create new therapeutics with potentially superior properties to that of HDL.
We recently reported on a panel of apoA-I mimetic peptides where we were able to delineate the separate functional properties of each peptide in vitro. 3 Some peptides were active as cholesterol acceptors with reduced anti-inflammatory and antioxidation capacity, while others had the inverse properties. In the current study, we tested several peptides from this panel in a mouse model of atherosclerosis to establish if differences in the in vitro capacity of each peptide translates into its corresponding effect in vivo and the ability of this to reduce atherosclerosis.
Materials and Methods
Detailed Methods section is available in the online-only Data Supplement.
Results

Effect of apoA-I Mimetic Peptides on Early Lesion Development
The peptides chosen for study, together with details outlining the functional capacity of each, were previously published 3 and are summarized in Table I in the online-only Data Supplement. The peptides included ELK-2A2K2E, potent in cholesterol efflux, ELKA-CH2, a selective inhibitor of CD11b expression in monocytes, ELK-2A, a selective inhibitor of VCAM-1 (vascular cell adhesion molecule 1) expression in endothelial cells, and 5A-CH1, which inhibits low-density lipoprotein (LDL) oxidation. In addition, we examined the synergistic effect of ELK-2A2K2E and 5A-C1 (each peptide was added at half the concentration compared with that when tested individually). This peptide combination was selected on the basis of reproducing, at least in vitro, all 4 of the antiatherogenic profiles under study ( Figure I in the online-only Data Supplement). Finally, the well-characterized and versatile peptide 5A was also studied under the same conditions. 4, 5 The effect of each peptide on the development and characteristic of atherosclerotic plaques in apolipoprotein E-deficient mice fed high-fat diet (HFD) was investigated.
In the first set of experiments, the effect of each peptide on the development of early atherosclerotic lesions in apolipoprotein E-deficient mice after 4 weeks of feeding with HFD was examined. En face analysis of the aorta is presented in Figure 1A through 1D and in Figure IIA in the online-only Data Supplement. All peptides have significantly reduced the abundance of atherosclerotic lesions to the same extent in total aorta ( Figure 1A ) and the aortic arch ( Figure 1B) . Few lesions were found in the thoracic ( Figure 1C ) or abdominal ( Figure 1D ) aorta, which were unaltered by any of the peptides. The development of atherosclerosis was then analyzed in sections of the aortic sinus. Again, all peptides reduced the size of atherosclerotic lesions, and the effect was similar for all tested peptides ( Figure 1E ; Figure IIIA in the online-only Data Supplement).
To characterize the effect of the peptides on the composition of the plaques, aortic sinus sections were analyzed for the abundance of CD68-positive cells (macrophages; Figure 1F ; Figure IIIB in the online-only Data Supplement), VCAM-1 (soluble and cellular; Figure 1G ; Figure IIIC in the online-only Data Supplement), collagen ( Figure 1H ; Figure IIID in the online-only Data Supplement), and nitrotyrosine ( Figure 1I ; Figure IIIE in the online-only Data Supplement). None of these were different to the vehicle control. It is important to recognize that parameters of plaque composition are presented relative to the plaque size. Because treatment with the peptides reduced plaque size, the absolute values of plaque composition parameters were also reduced; however, no difference between the effects of different peptides was found ( Figure To assess the effect of the peptides on systemic inflammation, we measured the levels of plasma cytokines after treatment with the peptides (Table II and Figure VI in the online-only Data Supplement). Across the panel of 13 cytokines measured, only elevation in interferon-β and interleukin-27 reached statistical significance, and overall effects were mild, with no consistent difference between the effects of different peptides.
Effect of apoA-I Mimetic Peptides on Development of Atherosclerotic Plaque
The potential synergistic effect of 2 peptides, ELK-2A2K2E and 5A-C1, chosen because together they reproduced all the key in vitro antiatherogenic properties, was further examined in an extended 12-week study.
Both peptides individually reduced total aorta abundance of atherosclerotic plaques by 30% to 50%, while the peptide combination showed no significant effect (Figure 2A 
Pharmacokinetics and Biodistribution of the Peptides
We then examined whether the coadministration of the peptides affected their pharmacokinetics and biodistribution. Peptides ELK-2A2K2E and 5A-C1 were labeled with Alexa 350 and Cascade yellow, respectively, and injected intraperitoneally into apolipoprotein E K/O mice, fed HFD for 2 weeks, either individually or as a 1:1 mixture. The pharmacokinetics of ELK-2A2K2E injected alone was similar to that observed in our previous study 6 (t 1/2 =2.25 hours), with 5A-C1 having a longer half-life (t 1/2 =3.8 hours; Figure IXA in the online-only Data Supplement). When the 2 peptides were injected together, the half-life of both peptides was identical (t 1/2 =3.8 hours; Figure IXB in the online-only Data Supplement). Both peptides were stable in vitro at 4°C for at least 7 days.
Next we investigated dynamics of distribution of both peptides among lipoprotein fractions when peptides were injected together. One hour after injection, a relatively large proportion of the peptides was degraded; however, most of the intact ELK-2A2K2E was found as an unbound peptide, with the remainder bound to HDL. Most of 5A-C1 was also found as an unbound peptide, with only minor proportion bound to HDL and LDL fractions ( Figure IXC in the onlineonly Data Supplement). After 2 hours, the distribution of ELK-2A2K2E was mostly unchanged, but relatively more 5A-C1 was found in HDL fraction ( Figure IXD in the onlineonly Data Supplement). After 6 hours, most of the peptides The peptides were injected intraperitoneally for 4 weeks into apoE −/− mice fed HFD. The dissected aorta was stained with Sudan IV and analyzed en face for abundance of atherosclerotic lesions in whole aorta (A), aortic arch (B), thoracic aorta (C), and abdominal aorta (D). The heart was dissected and the attached aortic sinus sectioned and stained to examine the lesion size and composition with Oil Red O stain for lesion size (E), for CD68 for macrophage contents (F) anti-whole and soluble VCAM-1 (vascular cell adhesion molecule 1) for lesion inflammation (G), Masson trichrome for collagen contents (H) and for nitrotyrosine (I) to determine oxidative stress of the lesion. Solid lines connect pairs with P<0.05; dashed lines connect pairs with P<0.01.
were degraded; the intact ELK-2A2K2E was evenly divided between unbound peptide, HDL, and LDL fractions, while intact 5A-C1 remained mainly unbound or in HDL fraction ( Figure IXE in the online-only Data Supplement). Thus, despite having been administered together, the 2 peptides distributed between lipoprotein fractions independently of each other.
Functionality of the Peptides in Plasma
We have then compared the cholesterol efflux in vitro to plasma collected from mice treated with peptides in vivo with cholesterol efflux to peptides added in lipid-free form or after adding peptides to hyperlipidemic mouse plasma ex vivo. The capacity of lipid-free peptides to support cholesterol efflux in vitro was consistent with that found in our previous study 3 ( Figure XA in the online-only Data Supplement). When the peptides were added to mouse plasma and incubated for 1 hour at 37°C, they statistically significantly, albeit modestly, increased the capacity of the plasma to support cholesterol efflux in vitro ( Figure XB and XC in the online-only Data Supplement). Interestingly, the differences between the peptides moderated: the peptides that shown little cholesterol efflux capacity in lipid-free form (5A-C1, ELKA-CH1, and 5A-CH1) were almost as effective as potent peptides when added to plasma. Similar trends were observed when plasma of mice treated with peptides in vivo was used as an acceptor, but the effects weakened, and most of them did not reach statistical significance ( Figure XD in the online-only Data Supplement). Thus, supplementation of plasma with peptides both in Figure 2 . The effect of apolipoprotein A-I (apoA-I) mimetic peptides on development of atherosclerotic plaque (12 weeks HFD feeding). The peptides were injected intraperitoneally for 12 weeks into apoE −/− mice fed HFD. The dissected aorta was stained with Sudan IV and analyzed en face for abundance of atherosclerotic lesions in whole aorta (A), aortic arch (B), thoracic aorta (C), and abdominal aorta (D). The heart was dissected and the attached aortic sinus sectioned and stained to examine the lesion size and composition with Oil Red O stain for lesion size (E), for CD68 for macrophage contents (F) anti-whole and soluble VCAM-1 (vascular cell adhesion molecule 1) for lesion inflammation (G), Masson trichrome for collagen contents (H) and for nitrotyrosine (I) to determine oxidative stress of the lesion. Solid lines connect pairs with P<0.05; dashed lines connect pairs with P<0.01.
vitro and in vivo improved plasma cholesterol efflux capacity, but the improvement was modest and similar for all peptides.
Finally, we tested if the peptides are lytic causing hemolysis. No hemolysis of murine red blood cells was caused by any of the peptides added at concentrations up to the maximum level found in plasma ( Figure XE in the online-only Data Supplement).
Discussion
ApoA-I mimetic peptides were designed to reproduce key elements of the atheroprotective properties of HDL (such as cholesterol efflux, anti-inflammation, and antioxidation) and to prevent the development of atherosclerosis in vivo. Because both objectives had been achieved, we sought to define which of those properties, if any, played the larger role. Our major finding was that they were equally potent in preventing the development of atherosclerosis but, more surprisingly, that none of the specific antiatherosclerotic elements observed using in vitro assays were observable in vivo.
There are several ways to interpret this data. It may be that all the elements examined had equal bearing on the ability of each peptide to prevent the development of atherosclerosis. However, given that none of these in vitro elements, on which each peptide was chosen, translated into the corresponding in vivo feature, it is more likely that the atheroprotective effect of these peptides occurs independently of these features by a different mechanism altogether. One such mechanism may be the recently reported atheroprotective effects of apoA-I mimetic peptides that is unrelated to mimicking HDL in the vascular milieu, instead targeting small intestine environment. According to this hypothesis, atheroprotection is achieved through the mitigation of the systemic inflammatory effects of the intestine-derived oxidized lipids 7, 8 or through modulation of transintestinal cholesterol efflux. 9 Another possibility is the ability of the peptides to enhance production of natural anti-ox-LDL antibodies. 10 However, it is important to recognize that the peptides tested in this study were not exhaustively characterized in relation to every potential antiatherogenic activity of HDL. For example, the ability of these peptides to stabilize ABCA1 (ATPbinding cassette transported A1) and reduce abundance of lipid rafts or improve vascular reactivity or their potential antiplatelet and antiapoptotic properties were not studied. Furthermore, the differences in key antiatherogenic property of the peptides, enhancing cholesterol efflux, leveled out when peptides were added to plasma ex vivo and in vivo, corresponding to their effect on development of atherosclerosis. This is consistent with findings of Tang et al, 11 indicating that the biological properties of the peptides are affected by their lipidation state.
Another finding of interest was that apoA-I mimetic peptides were more active in reducing the early stages of development of atherosclerosis than in mitigating a developed atherosclerotic plaque. Not only were the overall effects on atherosclerosis more pronounced after 4 weeks compared with 12 weeks of HFD feeding, but the effects were predominantly in thoracic aorta in the longer term study, where initiation of atherosclerosis was delayed when compared with the aortic arch. 12 This suggests that apoA-I mimetic peptides predominantly target early events in the pathogenesis of atherosclerosis, that is, inflammation and accumulation of cholesterol, which is consistent with findings of Wool et al. 10 However, while all the peptides reduced the lesion cholesterol accumulation, no effect on local inflammation was observed. The effects on levels of plasma cytokines were minimal, but increased proportion of anti-inflammatory GR1Lo monocytes in blood and reduced proportion in lymph nodes may be an indirect indication of systemic anti-inflammatory action of the peptides. We, thus, conclude that while apoA-I mimetic peptides are antiatherogenic, there is a discordance between the in vitro and in vivo functional properties of apoA-I mimetic peptides, which requires us to be cautious in our reliance on some of the standard assay systems commonly used. Determining the various in vitro functional properties of apoA-I mimetic peptide in plasma rather than in the lipid-free state most likely better reflects their physiological effect and better correlates with the observed in vivo effects of the peptides on atherosclerosis. The in vitro assessment of future apoA-I mimetic peptides should, therefore, be based on assays that use plasma as the matrix.
